269SC, LIMS Specialist, Translational Science

Job Code 269SC

Description

Fate Therapeutics is currently seeking a talented and highly motivated LIMS Specialist to support translational medicine, in vivo pharmacology, cell banking, and clinical departments. Successful candidates will translate business needs into technical requirements within the Company’s LIMS software application (Freezerworks). The successful candidate will manage LIMS configuration and support services for multiple projects and programs, while ensuring data integrity, and the timeliness of deliverables. In this role you will document the data and work flow needs of each program to develop and implement LIMS configuration plans to ensure optimal performance across interdepartmental lab & related work flows. The candidate must have strong expertise in the design, development, and deployment of LIMS services and processes aligned with strategic objectives of the Company, external resources, regulatory requirements, and best in class LIMS practices. This is a full-time position reporting to the SVP, Translational Medicine and is located at the Company’s corporate headquarters in San Diego, California.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 269SC.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.